European Archives - Page 841 of 984 - European Medical Journal

Continue
9 Mins
28 Jul 2016

Bridging to Transplant in Diffuse Large B Cell Lymphoma

Non-Hodgkin lymphoma (NHL) is the eighth most common malignancy worldwide. Diffuse large B cell lymphoma (DLBCL) is the most frequent subtype, accounting…
9 Mins
28 Jul 2016

Thrombocytopenia Caused By Inherited Haematopoietic Transcription Factor Mutation: Clinical Phenotypes and Diagnostic Considerations

Inherited thrombocytopenias comprise a heterogeneous group of blood disorders with abnormalities in genes related to glycoproteins and adhesion molecules…
2 Mins
28 Jul 2016

The Spectrum of Late Effects After Cancer: Lessons from Paediatric Oncology and the Value of International Collaboration

This presentation described the occurrence of late side effects (commonly described as ‘late effects’) in childhood cancer survivors (CCS), and how…
1 Mins
28 Jul 2016

Chronic Lymhocytic Leukaemia: Treatment of the Elderly

Chronic lymphocytic leukaemia (CLL) mainly affects elderly patients.1 With the increasing comorbidity burden and frailty in elderly patients, evaluation…
9 Mins
28 Jul 2016

The Relative Contributions of Germline Variation, Epimutation, and Somatic Mutation to Paediatric Leukaemia Predisposition

The next-generation sequencing era has repeatedly demonstrated that the amount of acquired somatic mutations in paediatric cancers can rarely account for…
16 Mins
28 Jul 2016

Current Management of Adult Acute Lymphoblastic Leukaemia: Emerging Insights and Outstanding Questions

Less than 50% of patients with adult acute lymphoblastic leukaemia (ALL) experience long-term survival and for those adults >60 years old, long-term…
7 Mins
28 Jul 2016

Management of Children With Sickle Cell Disease in Europe: Current Situation and Future Perspectives

Sickle cell disease (SCD) is the most common haemoglobinopathy worldwide and its frequency has steadily increased in Europe in the past decades. SCD is a…
EMJ
4 Mins
27 Jul 2016

Vital Lessons from Nigerian Mums on Diabetes

“Paul, that sugar you are adding to your tea is too much,” said my mother as I added the fourth cube to my teacup. She would say the same thing when…
26 Jul 2016

Introducing EMJ Rheumatology 3.1

United Kingdom, July 26, 2016: Welcome to this year’s edition of EMJ Rheumatology, packed full of exciting news and developments from throughout the past…
26 Jul 2016

Introducing New Biosimilars Into Current Treatment Algorithms

Three biosimilar products are now licensed for the treatment of rheumatic diseases in Europe. The European Medicines Agency (EMA) requires that similarity between a biosimilar and its reference product is demonstrated using a rigorous, stepwise process that includes extensive physicochemical and biological analytical testing, non-clinical pharmacology, clinical evaluations, and pharmacovigilance plans. Each